利拉魯肽和阿必魯泰是治療2型糖尿病的新靶點(diǎn)藥物，較已有的口服降糖藥降糖效果好、副作用較小，而且可以減輕體質(zhì)量，因此有廣闊的應(yīng)用前景。作為新一代降糖新藥，利拉魯肽是一種短效胰高血糖素樣肽-1（GLP-1）類似物，阿必魯泰是一種長效GLP-1類似物，兩者既有共同之處，又有區(qū)別?？偨Y(jié)這二種抗糖尿病新藥的臨床應(yīng)用和不良反應(yīng)研究進(jìn)展，為臨床合理用藥以及新藥研發(fā)提供思路。

Liraglutide and Albiglutide is a new target for the treatment of type 2 diabetes, than the hypoglycemic effect of oral hypoglycemic drugs, less side effects, but also can reduce weight, so it has broad application prospects. As a new generation of drugs, Liraglutide is a short acting glucagon like peptide-1 (GLP-1) analogs, Albiglutide a will is a long-acting GLP-1 analogues, both similarities and differences. The research progress of clinical application and adverse reaction of summarizing these two kinds of anti diabetic drugs, provide ideas for clinical rational use of drugs and drug development.